Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...
On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan Earthquake and the Fukushima Daiichi nuclear disaster. Fourteen years later ...
Zymeworks Inc. (ZYME), with a market capitalization of approximately $902 million, reported a net loss of $122.7 million for the fiscal year 2024, or $1.62 per diluted share. The company’s revenue saw ...
Zymeworks Inc. (ZYME), with a market capitalization of approximately $902 million, reported a net loss of $122.7 million for the fiscal year 2024, or $1.62 per diluted share. The company’s ...
AstraZeneca and Daiichi Sankyo also recently won the FDA’s approval for another ADC they are working on together. Datroway, which also carries a topoisomerase I inhibitor but instead targets the TROP2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback